Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Sherman
J H
JH
Departments of Neurological Surgery,University of Virginia, Charlottesville, VA 22908, USA.
Aregawi
D G
DG
Lai
A
A
Fathallah-Shaykh
H M
HM
Bierman
P J
PJ
Linsky
K
K
Larner
J M
JM
Newman
S A
SA
Schiff
D
D
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009901:Optic Nerve Diseases / Q000139:chemically induced*; D012189:Retrospective Studies
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab